Login
← Go Back
Bafna Pharmaceuticals
BAFNAPH · Pharma > Pharmaceuticals & Drugs · Chairman: Shanmugam Hemalatha Listing date: Nov. 13, 2012
Stock Price vs Company Growth
1d
1.6%
1w
11.4%
1m
13.1%
3m
23.9%
6m
4.7%
1y
106.7%
5y
1.9%
10y
17.7%
all
9.3%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 155 1.6%
108
216
Company Overview
Sales
151 Cr
Growth: 2.1%
Profit after Tax
11.1 Cr
Growth: 14.9%
Micro Cap
367 Cr
P/E: 45.0x
Industry P/E: 31.1x
Fundamentals
Sales (Cr) ₹ 151
Growth 2.1%
EBITDA 10.6%
P/S 2.5x
Dividend 0.0%
P/E 45.0x
Book Value ₹ 40.6
PEG Ratio 21.0x
ROE 12.0%
P/B 3.9x
Shareholding Pattern
Institutions
Promoters
Srjr Lifesciences Llp
90.0 %
Paras Bafna
0.21 %
Navin Bafna M
0.17 %
Amribai Bafna
0.01 %
Others
Monarch Networth Finserve Private Limited
1.4 %
Increase    Decrease    No change
Company Profile Detailed
:The company is engaged in the manufacturing of pharmaceutical products. It exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries.Product Range:Anti-DiabeticCardiovascularAnti-HypertensiveBi-Layer AntihypertensiveAwards, accreditations and recognition1995: The company was awarded the WHO GMP.2005: The company bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka.
Investors (54)
mahaveer...
paras.ba...
sasikala...